VivoSeq
Oncology

Locally-Advanced Rectal Cancer

6

Pipeline Programs↗

73

Active Trials↗

6

Companies Involved↗

Locally-advanced Rectal Cancer is an early-stage landscape with 6 programs across 6 companies. The most active players are Johnson & Johnson, Roche, GSK.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

43/100

Mech. Concentration

100/100

Completion Rate

85/100

Attrition Rate

4/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2Roche logo

Roche

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalSuzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalRadiation Therapy Oncology Group logo

Radiation Therapy Oncology Group

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

141

clinical trials

Recruiting40 · 28%
Completed33 · 23%
Unknown status29 · 21%
Not yet recruiting18 · 13%
Active, not recruiting15 · 11%
Terminated4 · 3%
Other2 · 1%

Clinical Trials

Trial Activity

141 trials

Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
Recruiting·—·Phase 2·NCT07040098·228 enrolled
UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer
Recruiting·ZZhejiang Cancer Hospital·Phase 4·NCT05148767·606 enrolled
Genotype-driven Weekly Irinotecan Liposomes in Combination With Capecitabine-based Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer
Recruiting·ZZhejiang Cancer Hospital·Phase 1·NCT06300489·30 enrolled
Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer
Recruiting·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT05136326·21 enrolled
Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer
Recruiting·FFudan University·Phase 2·NCT07154316·138 enrolled
TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer
Recruiting·National Cancer Center Hospital East·Phase 3·NCT05646511·608 enrolled
SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer
Recruiting·UUniversity of Miami·Phase 1·NCT05412082·25 enrolled
Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer
Recruiting·YYong Zhang,MD·Phase 3·NCT06017583·48 enrolled
Neoadjuvant FOLFIRINOX and Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Patients
Recruiting·MMenoufia University·Phase 2·NCT06812728·100 enrolled
Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy
Recruiting·SSun Yat-sen University·Phase 2·NCT05965531·65 enrolled
CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer
Recruiting·SShanghai Changzheng Hospital·Phase 2·NCT05585814·30 enrolled
Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)
Recruiting·HHebei Medical University Fourth Hospital·Phase 2·NCT07057089·90 enrolled
CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer
Recruiting·FFudan University·Phase 2·NCT06281405·192 enrolled
Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）
Recruiting·TThe Affiliated Hospital of Qingdao University·Phase 2·NCT06647680·35 enrolled
Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial
Recruiting·—·Phase 1·NCT06834126·36 enrolled
Page 1 of 10

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)